ART Advanced Research Technologies to be Present at the Annual Meeting of the Radiological Society of North America (RSNA) in Ch
November 26 2007 - 9:32AM
Marketwired
MONTREAL, CANADA (TSX: ARA), a Canadian medical device company
and a leader in optical molecular imaging products for the
healthcare and pharmaceutical industries, is pleased to announce
its participation at the 93rd annual meeting of the Radiological
Society of North America (RSNA) being held at McCormick Place in
Chicago, from November 25 to 30, 2007. ART will showcase the
SoftScan� system, an optical medical imaging device designed to
improve the diagnosis and treatment monitoring of breast cancer, at
its booth (#4074) located in the South Building Exhibit Hall of
McCormick Place.
"ART believes that there is a large market opportunity for the
SoftScan breast imaging device, to address 'blind spots' offered by
other imaging modalities such as mammography," said Sebastien
Gignac, ART's President and CEO. "At the 2007 RSNA, we will be
showing how SoftScan is doing this, through recent clinical results
obtained for indications in diagnostic imaging, as well as for
treatment monitoring. In particular, the treatment monitoring
application currently under investigation in study sites in Canada
and the United States, offers a clear value proposition to clinics,
radiologists and third-party payers, helping to ensure effective
treatment and reduce chemotherapy drug costs," added Mr.
Gignac.
Following the regulatory approvals obtained for the
commercialization of the device in the course of the past year, the
device is to be sold in Canada, Europe and other markets outside
the United States, as well as globally for investigative use in
drug development research settings.
About the SoftScan� system
The SoftScan� optical breast imaging system has been designed
first as a complementary diagnostic tool to mammography, with
ultimate uses in the detection and treatment monitoring of breast
cancer. Its non-invasive, painless approach uses time-domain
optical imaging technology, which may allow clinicians to better
locate and characterize breast tumors as benign or malignant and
could provide faster assessment of therapeutic effectiveness.
Unlike mammography whose use must be strictly limited, the SoftScan
system emits no radiation and can be safely used as often as needed
to monitor patients. The device was created and developed by ART
Advanced Research Technologies Inc., and has obtained regulatory
approvals for its commercialization in Canada and in Europe.
About ART
ART Advanced Research Technologies Inc. is a leader in molecular
imaging products for the healthcare and pharmaceutical industries.
ART has developed products in medical imaging, medical diagnostics,
disease research, and drug discovery with the goal of bringing new
and better treatments to patients faster. The Optix� optical
molecular imaging system, designed for monitoring physiological
changes in living systems at the preclinical study phases of new
drugs, is distributed directly by ART in North America and Europe
and is used by industry and academic leaders worldwide. The
SoftScan� optical breast imaging device is designed to improve the
diagnosis and treatment of breast cancer. ART is commercializing
the SoftScan optical medical imaging device via a global strategic
alliance with GE Healthcare, a world leader in mammography and
imaging. Finally, the Fenestra� line of molecular imaging contrast
products provide image enhancement for a wide range of preclinical
Micro CT applications allowing scientists to see greater detail in
their imaging studies, with potential extension into other major
imaging modalities. The distribution of the Fenestra line of
imaging contrast agents is made through GE Healthcare Bio-Science
KK in Japan and is sold directly by the Company in the rest of the
world. ART's shares are listed on the TSX under the ticker symbol
ARA. For more information on ART, visit our website at www.art.ca
.
This press release may contain forward-looking statements
subject to risks and uncertainties that would cause actual events
to differ materially from expectations. These risks and
uncertainties are described in the most recent Annual Information
Form and the financial statements for the year ended December 31,
2006, available on SEDAR (www.sedar.com).
Contacts: ART Advanced Research Technologies Inc. Jacques Bedard
Chief Financial Officer 514-832-0777 jbedard@art.ca www.art.ca
Aclara Resources (TSX:ARA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Aclara Resources (TSX:ARA)
Historical Stock Chart
From Jul 2023 to Jul 2024